If you have an effective way to streamline trials, I think people would be very very interested in it, regardless of the liability argument (of which I am very very skeptical). Already trials are usually pushed to be as fast as possible, because the patent clock runs out on treatments, so a faster answer is usually the best answer to achieve for investors.
